Tadocizumab
Jump to navigation
Jump to search
Monoclonal antibody | |
---|---|
Type | Fab fragment |
Source | Humanized (from mouse) |
Target | Integrin αIIbβ3 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C2107H3252N562O673S12 |
Molar mass | 47.6 kg/mol g·mol−1 |
![]() ![]() |
Tadocizumab is a humanized monoclonal antibody that acts on the cardiovascular system.[1] It binds to integrin αIIbβ3, a fibrinogen and fibronectin receptor found on platelets.[2]
The drug is designed for the treatment of patients undergoing percutaneous coronary interventions. It was developed by Yamanōchi Pharma America, Inc.[1]
References[edit]
- ^ a b Statement On A Nonproprietary Name Adopted By The USAN Council - Tadocizumab, American Medical Association.
- ^ Molecular cell biology. Lodish, Harvey F. 5. ed. : – New York : W. H. Freeman and Co., 2003, 973 s. b ill. ISBN 0-7167-4366-3
![]() | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
![]() | This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it. |